Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Abstract INTRODUCTION Predicting the rate of cognitive decline and the likelihood of progression to dementia remains a critical unmet need in clinical settings. METHODS We assessed progression to mild cognitive impairment (MCI) and all‐cause dementia in 492 individuals from the TRIAD, ADNI, and HABS‐HD cohorts followed for an average of 2.49 years. Amyloid‐positive participants were staged according to the Alzheimer's Association biological staging framework (A+T 2 ‐/A+T 2MTL +/A+T 2MOD +/A+T 2HIGH +). RESULTS Cognitively unimpaired (CU) individuals in the A+T 2MTL +, A+T 2MOD +, and A+T 2HIGH + biological Alzheimer's disease (AD) stages were at significantly higher risk of clinical progression compared to non‐AD CU individuals. In individuals with MCI, advanced tau stage was associated with an 83% likelihood of developing dementia over 4 years. Biological AD staging demonstrated superior accuracy in predicting clinical progression compared to amyloid‐PET (positron emission tomography) status, tau‐PET status, and demographic information. All tau‐PET‐positive individuals showed a significantly faster rate of cognitive decline than non‐AD controls, with the A+T 2HIGH + stage showing the steepest rate of decline ( p < 0.001). DISCUSSION Our results highlight the prognostic value of biological AD staging. Highlights Cognitively unimpaired (CU) individuals in all tau‐PET (positron emission tomography)–positive biological Alzheimer's disease (AD) stages were at significantly higher risk of clinical progression compared to individuals without AD. In individuals with mild cognitive impairment (MCI), only the A+T 2HIGH + stage reached a point where 50% of individuals had progressed to all‐cause dementia, after 2.36 years. Biological AD staging demonstrated superior accuracy in predicting clinical progression to dementia compared to other PET biomarkers and demographic information. All tau‐PET‐positive individuals showed a significantly faster rate of cognitive decline than individuals without AD, with the A+T 2HIGH + stage showing the steepest rate of decline.

What this study adds

Evidence grade: Low

The record lists 492 participants. This study found that biological Alzheimer's disease staging, based on amyloid and tau PET, predicted progression to mild cognitive impairment and dementia better than amyloid PET status, tau PET status, or demographic information alone. It does not test a treatment or cure, but it suggests this staging may help identify who is at higher risk of decline.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Trudel, L., Therriault, J., Macedo, A. C., Servaes, S., Hosseini, S. A., Bezgin, G., et al. (2025). Rates of clinical progression according to biological Alzheimer's disease stages. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70624

Vancouver

Trudel L, Therriault J, Macedo AC, Servaes S, Hosseini SA, Bezgin G, et al. Rates of clinical progression according to biological Alzheimer's disease stages. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70624. PMID: 40951978.

BibTeX

@article{trudel2025-40951978,
  author  = {Trudel, Lydia and Therriault, Joseph and Macedo, Arthur C. and Servaes, Stijn and Hosseini, Seyyed Ali and Bezgin, Gleb and Rahmouni, Nesrine and Chan, Tevy and others},
  title   = {{Rates of clinical progression according to biological Alzheimer's disease stages}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70624},
  pmid    = {40951978},
  url     = {https://doi.org/10.1002/alz.70624}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that biological Alzheimer's disease staging, based on amyloid and tau PET, predicted progression to mild cognitive impairment and dementia better than amyloid PET status, tau PET status, or demographic information alone. It does not test a treatment or cure, but it suggests this staging may help identify who is at higher risk of decline.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 49 of 100.49 of 100 points earned51 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 492 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 9 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.0 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 5.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Pedro Rosa‐Neto: h-index 89 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Southern California: institution h-index 1,521 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 8 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40951978)
Free to read 2 / 2 Free to read
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 30.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Mild cognitive impairment from nearby years

Also in Mild cognitive impairment

76 studies in the library are filed under Mild cognitive impairment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Mild cognitive impairment hub.

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →